tirzepatide and parkinson's disease GLP-1 does not slow progression in phase 3 study Progress in Parkinson disease and

Glutathione: Brightens Skin from the Inside Out Step 1: Glutathione is absorbed into the bloodstream and transported to cells

PlexusDx maintains no affiliate deal, partnership, or paid tie with Noom or its parent company

J Cell Physiol 232:6977

Tirzepatide, as the first GLP-1/GIP dual receptor agonist, demonstrated greater benefits in blood glucose control and weight reduction compared with GLP-1 single receptor agonists like semaglutide and dulaglutide, induced by the combined activation of both receptors.23,26 The latest results from the SURMOUNT-5 trial, published in May 2025, indicate that in obese individuals without diabetes, tirzepatide led to greater reductions in both weight and waist circumference compared with semaglutide

Secondo un nuovo studio pubblicato su The Lancet, leccesso di peso associato a un aumento del rischio di ricovero ospedaliero e di morte per malattie infettive causate da virus, funghi, parassiti e batteri